Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open Label Extension of Vormatrigine in Adult Epilepsy
NCT07287163Phase 3Enrolling by invitation
- Sponsor
- Praxis Precision Medicines
- Start
- Oct 2025
- Primary completion
- May 2028
- Modality
- Classical Binding Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of vormatrigine in epilepsy, focal seizure, generalized tonic-clonic seizure (GTCS), sponsored by Praxis Precision Medicines. Started Oct 2025; status: enrolling by invitation.
02
Drugs
vormatrigine
03
Conditions
epilepsyfocal seizuregeneralized tonic-clonic seizure (GTCS)
Beyond the preview
Go deeper on NCT07287163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07287163.